Sentinel lymph node biopsy for patients with cutaneous desmoplastic melanoma

被引:74
作者
Gyorki, DE
Busam, K
Panageas, K
Brady, MS
Coit, DG
机构
[1] Mem Sloan Kettering Canc Ctr, Gastr & Mixed Tumor Serv, Dept Surg, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Surg Pathol, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Biostat, New York, NY 10021 USA
关键词
desmoplastic melanoma; sentinel lymph node biopsy; local recurrence; survival;
D O I
10.1245/ASO.2003.04.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Although desmoplastic melanoma (DM) often presents at a locally advanced stage, nodal metastases are rare. We describe our experience with lymphatic mapping and sentinel lymph node biopsy (SLNB) in patients with DM to characterize the biological behavior of these tumors. Methods: Twenty-seven patients with cutaneous DM underwent wide excision and attempted SLNB between 1996 and 2001. All pathology was reviewed by a single dermatopathologist (KB). Clinical and histological features were recorded. Results: There were 20 male and 7 female patients. The median age was 64 years (range, 35-83 years). The head and neck was the most commonly involved anatomical region (n = 14). The median Breslow thickness was 2.2 mm. Twenty-four patients underwent successful SLNB. No patient had a positive sentinel node. At a median follow-up of 27 months, five patients recurred (four systemic and one local); all five. had undergone successful SLNB. Two of these patients died of disease, two are alive with disease, and one remains alive and disease free. No patient experienced failure in a regional nodal basin. Conclusions: DM is a biologically distinct form of melanoma, with a very low incidence of regional lymph node metastases, either at presentation or in long-term follow-up. This biology should be considered when designing rational treatment strategies for these patients.
引用
收藏
页码:403 / 407
页数:5
相关论文
共 20 条
[1]  
CARLSON JA, 1995, CANCER, V75, P478, DOI 10.1002/1097-0142(19950115)75:2<478::AID-CNCR2820750211>3.0.CO
[2]  
2-O
[3]   Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: Review of a large single-institutional experience with an emphasis on recurrence [J].
Clary, BM ;
Brady, MS ;
Lewis, JJ ;
Coit, DG .
ANNALS OF SURGERY, 2001, 233 (02) :250-258
[4]  
COIT DG, 2002, SENTINEL LYMPH NODE, P135
[5]  
CONLEY J, 1971, CANCER, V28, P914, DOI 10.1002/1097-0142(1971)28:4<914::AID-CNCR2820280415>3.0.CO
[6]  
2-E
[7]  
EGBERT B, 1988, CANCER, V62, P2033, DOI 10.1002/1097-0142(19881101)62:9<2033::AID-CNCR2820620927>3.0.CO
[8]  
2-E
[9]   Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients [J].
Gershenwald, JE ;
Thompson, W ;
Mansfield, PF ;
Lee, JE ;
Colome, MI ;
Tseng, CH ;
Lee, JJ ;
Balch, CM ;
Reintgen, DS ;
Ross, MI .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :976-983
[10]   DESMOPLASTIC MALIGNANT-MELANOMA AND ITS VARIANTS - A STUDY OF 45 CASES [J].
JAIN, S ;
ALLEN, PW .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1989, 13 (05) :358-373